Cooment: Crosby et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet Oncol 2013. (7)

摘要

Summary: The SCOPE 1 trial was a phase 2/3 randomized trial conducted in the United Kingdom comparing cisplatin/ capecitabine and radiation with or without cetuximab. Patients were eligible if they had stage I, II, or III disease and were recommended definitive chemoradiation. All patients were required to have endoscopic ultrasound staging, but positron emission tomography (PET) was optional. Treatment in the control arm was cisplatin 60 mg/m2 on day 1 and capecitabine 625 mg/m2 twice daily on days 1 through 21 for 4 cycles with radiation therapy (RT) delivered to 50 Gy at 2 Gy per fraction given during cycles 3 and 4.